Medtronic ICD Leads
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Medtronic ICD Leads you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Medtronic ICD Leads law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Medtronic ICD Leads use the related topic links on the far right.
Medtronic ICD Leads
Medtronic has suspended sales of the Sprint Fidelis defibrillator leads. 5 patient deaths and other life-threatening complications have been reported.
On October 15, 2007 Medtronic announced it was voluntarily suspending distribution of its Sprint Fidelis defibrillation leads.
Physicians were first notified in March 2007 about the fracture rate. Since then additional data on adverse events accumulated an prompted the the recall. Medtronic Sprint Fidelis® Recall List
The following model numbers are the defibrillator leads that have been recalled:
- Sprint Fidelis 6930
- Sprint Fidelis 6931
- Sprint Fidelis 6948
- Sprint Fidelis 6949
The Sprint Fidelis lead may have also been used to connect defibrillators manufactured by other companies such as Guidant, Boston Scientific, and St. Jude.
Medtronic ICD Leads In The News
Medtronic Announces FDA Approval of New Vision 3D Wireless Implantable Cardiac DevicesMINNEAPOLIS & SAN FRANCISCO----Leading into Heart Rhythm 2008, the pre-eminent worldwide gathering of cardiologists specializing in electrophysiology, Medtronic, Inc. today announced U.S.
Medtronic Announces FDA Approval Of New Vision 3D Wireless Implantable Cardiac DevicesLeading into Heart Rhythm 2008, the pre-eminent worldwide gathering of cardiologists specializing in electrophysiology, Medtronic, Inc. (NYSE: MDT) announced U.S.
Medtronic Announces FDA Approval of New Vision 3D Wireless Implantable Cardiac DevicesLeading into Heart Rhythm 2008, the pre-eminent worldwide gathering of cardiologists specializing in electrophysiology, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the first wave of cardiac rhythm disease management therapies under the new Vision 3D(TM) portfolio, which will comprise a full line of implantable cardioverter-defibrillators ...
